- 著者
- Yoshimoto Noriyuki Ogawa Kaoru Ogawa Satoshi
- 出版者
- IEEE
- 雑誌
- IEEE Transactions on Applied Superconductivity (ISSN:10518223)
- 巻号頁・発行日
- vol.14, no.2, pp.1600-1603, 2004-01-01
- 被引用文献数
- 1
Novel self-organization molecules, n-mercapto-alkyl benzo-annelated tetrathiafulvalenes (BTTF), have been synthesized. Exposure of polycrystalline Au and oriented crystalline Au (111) surfaces to organic solution of the novel BTTF derivatives in high magnetic field results in the binding of the derivatives to Au and the formation of highly-oriented self-assembled monolayers (SAMs) with redox active tetrahia-fulvalene (TTF) unit. The electrochemical properties were confirmed in the monolayer state. A comparison between SAMs on polycrystalline Au having a rough surface andon oriented crystalline Au (111) having a flat surface suggested that the well-oriented alkyl-chain layers in the SAMs could be blockade for the electron transfer between the TTF unit and the Au substrate.
- 著者
- Yamashita Takeshi Ogawa Satoshi Aizawa Yoshifusa Atarashi Hirotsugu Inoue Hiroshi Ohe Tohru Okumura Ken Kato Takao Kamakura Shiro Kumagai Koichiro Kurachi Yoshihisa Kodama Itsuo Koretsune Yukihiro Saikawa Tetsunori Sakurai Masayuki Sugi Kaoru Nakaya Haruaki Nakayama Toshio Hirai Makoto Fukatani Masahiko Mitamura Hideo Yamazaki Tsutomu
- 出版者
- 社団法人日本循環器学会
- 雑誌
- Circulation journal : official journal of the Japanese Circulation Society (ISSN:13469843)
- 巻号頁・発行日
- vol.67, no.9, pp.738-741, 2003-08-20
- 被引用文献数
- 22 50
The Japanese Rhythm Management Trial for Atrial Fibrillation (J-RHYTHM study) is a randomized comparative evaluation of rate control and rhythm control, both combined with antithrombotic therapy, as therapeutic strategies for the treatment of atrial fibrillation (AF). This study differs from the earlier AFFIRM and RACE studies in that it has a composite primary end-point representing mortality and also physical/psychological disablement (total mortality, symptomatic cerebral infarction, systemic embolism, major bleeding, hospitalization for heart failure requiring intravenous administration of diuretics, and patient disablement). Patients' will to change the therapeutic strategy to the other is also considered as an end-point representing disablement under the assigned strategy. The secondary end-point includes quality of life scores and the efficacy and safety of drugs used in treating AF. The J-RHYTHM study emphasizes patient-reported experience and perception of AF-specific disablement, and the safety of antiarrhythmics available in Japan; it will follow 2,600 patients treated at more than 150 sites in Japan for a 3-year period. (Circ J 2003; 67: 738-741)